Search
Nisoxetine
go.drugbank.com/drugs/DB09186ExperimentalNisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.
ATG-101
go.drugbank.com/drugs/DB17162InvestigationalATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
RO7296682
go.drugbank.com/drugs/DB17531InvestigationalRO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells. … RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Betaprodine
go.drugbank.com/drugs/DB01473ExperimentalIllicit(From Martindale, The Extra Pharmacopoeia, 30th ed, p1067) … An opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.
Asapiprant
go.drugbank.com/drugs/DB20492InvestigationalAsapiprant is under investigation in clinical trial NCT04705597 (Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That
CYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Paclitaxel docosahexaenoic acid
go.drugbank.com/drugs/DB05297InvestigationalA combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
Chlorfenson
go.drugbank.com/drugs/DB05377ExperimentalChlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.
RDP58
go.drugbank.com/drugs/DB06566ExperimentalRDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.